全球痛风药物市场-2022-2029

市场动态

全球痛风药物市场的增长归因于生活方式的改变、饮酒量的增加、肥胖和肾臟疾病的增加、高嘌呤饮食，以及由于多种药物利尿剂导致痛风在世界范围内的流行。市场增长的主要动力之一。

在预测期内，生物製剂的日益普及和再生医学研发的增加预计将推动全球痛风治疗市场。

推动市场增长的主要因素是越来越多地采用生物製剂和增加再生医学的研发，以及提高诊断成像模式的技术进步。这种情况可以通过使用非甾体抗炎药、皮质类固醇、秋水仙碱和降尿酸剂等药物来治疗或预防。

生物製剂正在迅速普及，并正在以更有效的方式取代 NSAID 和皮质类固醇。因此，生物製品领域预计将快速扩张，并可能在预测期内收购痛风疗法推动市场增长。

监管机构不断增加的产品批准预计将推动痛风治疗市场的增长。製造商正在采用收购与合作以及新产品开发策略来挖掘大部分患者群体未满足的需求。

目前正在开发新药，例如阿卤芬酸盐，它假定靶向肾尿酸转运蛋白，主要是 URAT1 和 OAT4，以用作降尿酸剂。此外，降尿酸药物用作痛风性关节炎的对症治疗、一线药物或联合治疗。

与抗痛风药物相关的副作用可能会阻碍市场增长

根据美国食品和药物管理局 (FDA) 的数据，用于治疗痛风的处方药在过去 8 年中因有时会出现严重的副作用而在美国造成 10 人死亡。秋水仙碱是一种广泛用于治疗痛风的强效抗炎药，已使用近 40 年，使其成为痛风患者一线治疗的可用选择之一。据FDA统计，共有17种秋水仙碱产品获得许可，每年全国销售约3800万片秋水仙碱片剂。然而，从 2011 年到今年 8 月，FDA 收到了 353 份报告表明该药物有副作用，其中大多数是肾功能或肝功能受损的患者，估计有 10 人死亡。我在这里。肾或肝功能受损的人，或同时服用其他慢性病药物的人，可能会因秋水仙碱而出现严重的副作用。

此外，可使用皮质类固醇（如泼尼松）来减轻疼痛和炎症。这些药物会增加血糖和血压并引起情绪变化。副作用可能包括噁心、腹泻和呕吐。在日本、欧洲和美国，已有患者在使用苯溴马隆时死于肾功能衰竭的报导。由于副作用，医生倾向于为患有肾臟或肝臟问题的人开较低剂量的秋水仙碱。因此，药物副作用等因素可能会抑制市场增长。

行业分析

全球痛风治疗市场根据波特五力、监管分析、供应链分析、定价分析、管道、未满足的需求和流行病学等各种行业因素对市场进行了深入分析。 .

COVID-19 影响分析

预计 COVID-19 的爆发将在预测期内影响痛风治疗市场的增长。根据 CreakyJoints 的说法，到 2020 年 5 月，痛风患者可能被认为属于潜在的 COVID-19 并发症的高危人群。世界各地的冠状病毒 (COVID-19) 大流行和封锁正在影响各行各业公司的财务状况。私营医疗保健部门也是受 COVID-19 大流行严重影响的部门之一。

随着 COVID-19 大流行的持续，几家公司正在测试治疗它的药物。例如，製药商 Glenmark Pharmaceuticals 表示，2020 年 6 月 22 日，抗病毒药物 favipiravir (Fabiflu) 被批准用于治疗轻度至中度 COVID-19 患者，并在一周内实现全面商业化。印度药品监管局已批准该抗病毒药物用于“限制性紧急使用”用于轻度至中度病例，这些病例占 COVID-19 感染的大部分。

一项随机、开放标籤的研究表明，用于治疗痛风和风湿性疾病的抗炎药秋水仙碱可能是治疗 COVID-19 的有前景的药物。 GRECCO-19 试验（Greek Study on the Effects of Colchicine in the Effects of COVID-19 Complications Prevention）随机分配了 105 名 COVID-19 患者接受标准治疗或标准治疗加秋水仙碱治疗 3 週，共纳入 19 名患者。结果表明，秋水仙碱治疗组缩短了临床恶化的时间，儘管在心臟或炎症生物标誌物方面没有显着的组间差异。

本报告提供了大约 45 多个市场数据表、40 多个图表和 180 页有关全球痛风药物市场的信息。

内容

第一章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

• 市场影响因素
  • 驱动程序
    • 扩大生物製剂的采用
    • 增加与再生医学相关的研发
  • 约束因素
    • 与抗痛风药物相关的副作用
  • 商机
  • 影响分析

第五章行业分析

• 波特五力分析
• 监管分析
• 供应链分析
• 定价分析
• 管道分析
• 未满足的需求
• 流行病学

第 6 章 COVID-19 分析

• COVID-19 的市场分析
  • COVID-19 之前的市场情景
  • COVID-19 的当前市场情景
  • COVID-19 后或未来情景
• COVID-19 期间的价格动态
• 供需范围
• 大流行期间与市场相关的政府举措
• 製造商的战略举措
• 总结

第 7 章按药物类别

• 非甾体抗炎药 (NSAID)
  • 布洛芬
  • □普生
  • 消炎痛
  • 塞来昔布
  • 其他
• 高尿酸血症药（降尿酸药）
  • 黄嘌呤氧化□抑製剂
    • 别嘌醇（洛普林、齐罗普林）
    • 非布司他（尿酸）
  • 降尿酸药
    • 苯溴马隆
    • 丙磺舒
    • 磺□酮
  • 尿酸□
    • 果胶□
    • 拉布立克□
• 肾上腺皮质类固醇
  • 地塞米松（Dexpak）
  • 甲泼尼龙（Medrol）
  • 泼尼松龙（Omnipread）
  • 泼尼松 (Raios)
  • 曲安西龙（Aristospan）
• 秋水仙碱
  • 科尔克里斯
  • 缓解
• 其他

第 8 章按应用程序

• 急性痛风
• 慢性痛风

第 9 章，最终用户

• 医院药房
• 药店
• 在线频道
• 其他

第 10 章按地区划分

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第 11 章竞争格局

• 主要发展和战略
• 公司份额分析
• 治疗分类基准
• 值得关注的重点公司列表

第 12 章公司简介

• 诺华国际公司
  • 公司概况
  • 药物类别组合和说明
  • 主要亮点
  • 财务摘要
• GlaxoSmithKline PLC
• Lannett Company, Inc
• Mylan NV
• Boehringer Ingelheim
• Horizon Therapeutics plc
• Regeneron Pharmaceuticals
• Takeda Pharmaceutical Company Ltd
• Teijin Pharma Ltd
• Romeg Therapeutics, LLC

第 13 章全球痛风药物市场-DataM

Market Overview

Gout Therapeutics Market size was valued US$ 1.9 billion in 2021 and is estimated to reach US$ 4.1 billion by 2029, growing at a CAGR of 8.2% during the forecast period (2022-2029).

Gout is a type of inflammatory arthritis caused by the overabundance of uric acid in the body, either producing too much or excreting too little. Gout can be acute and chronic. Acute gout mostly affects the major extremity joint, with the small joints of the hands and feet the most affected. In chronic gout, hard swellings (known as tophi) can form on the joints made of uric acid and grow large, even breaking through the skin. The global gout therapeutics market is impacted by several factors such as the rising prevalence of gout globally due to changes in lifestyle, increasing alcohol consumption, increasing obesity & kidney diseases, high purine diet, and several medications diuretics.

Market Dynamics

The global gout therapeutics market growth is driven by the rising prevalence of gout globally due to changes in lifestyle, increasing alcohol consumption, increasing obesity & kidney diseases, high purine diet, and several medications diuretics are among the key factors driving the market growth.

Growing adoption of biologics and increasing R&D on regenerative medicines are expected to drive the global gout therapeutics market during the forecast period.

The major factors driving the growth of the market are the rising adoption of biologics and increasing R&D on regenerative medicines, technological advancements in imaging modalities improved. This condition can be treated or prevented with the use of drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents.

Biologics have witnessed rapid adoption and are replacing NSAIDs and corticosteroids owing to better results. Hence, the biologics segment is anticipated to expand at a rapid pace and is likely to gain gout therapeutics which drive the market growth in the forecast period.

Increasing product approvals by regulatory authorities are expected to drive the growth of the gout disease treatment market. Manufacturers are adopting acquisition & collaboration and new product development strategies to tap the unmet needs of a large proportion of the patient pool.

The new medication is being developed, such as arhalofenate, which is estimated to target renal transporters of uric acid, primarily URAT1 and OAT4, acting as uricosuric agents. Moreover, urate-lowering drugs are utilized for the symptomatic treatment of gout arthritis, as a first line of therapy or in combination therapy.

Side effects associated with gout therapeutics are likely to hinder the market growth

A prescription medicine used to treat gout is suspected to have caused 10 deaths in the U.S over the past eight years due to side effects that can sometimes be severe, according to the Food and Drug Administration (FDA). Colchicine, a strong anti-inflammatory that is widely used to treat gout, has been used for nearly 40 years and is one of the available options for the frontline treatment of people with gout. A total of 17 colchicine products have been licensed by the FDA and about 38 million colchicine tablets are sold in the nation each year, the FDA said. However, from 2011 to August this year, the FDA received 353 reports suggesting adverse reactions to the drug, mostly among patients with renal and liver dysfunction, with 10 deaths believed to be linked to the problem. People with renal or hepatic impairment and those who also take other drugs for chronic diseases could experience serious side effects from colchicine.

In addition, corticosteroids, such as prednisone, can be prescribed to reduce pain and inflammation. They can increase blood sugar levels and blood pressure and may induce mood changes. Side effects can include nausea, diarrhea and vomiting. In Japan, Europe and the US, there have been reports of patients dying of renal failure after using benzbromarone, because of the side effects, doctors tend to prescribe low-dose colchicine for people with renal or hepatic impairment. Thus, factors such as the adverse effects of the drugs may restrain the market growth.

Industry Analysis

The global gout therapeutics market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis, pricing analysis, pipeline, unmet needs, epidemiology.

COVID-19 Impact Analysis

The Covid - 19 pandemic is expected to impact the growth of the gout therapeutics market over the forecast period. According to CreakyJoints, in May 2020, people with gout may be considered in a higher-risk group for potential COVID-19 complications. The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one of the sectors, which has been majorly impacted by the COVID-19 pandemic.

With the ongoing COVID-19 pandemic, several companies are testing their drugs for their treatment. For instance, on June 22nd, 2020, the anti-viral drug Favipiravir (Fabiflu) was approved for the treatment of mild to moderate COVID-19 patients and will be commercialized full scale in a week, says drugmaker Glenmark Pharmaceuticals. The Drug Controller General of India approved the anti-viral for 'restricted emergency use' for treatment of mild to moderate cases, which accounts for a majority of COVID-19 infections.

Colchicine, an anti-inflammatory drug used to treat gout and rheumatic disease, may be a promising treatment for COVID-19, a randomized, open-label trial suggests. In the Greek Study on the Effects of Colchicine in COVID-19 Complications Prevention (GRECCO-19), investigators randomly assigned 105 patients who had COVID-19 to receive either the standard of care or the standard of care plus colchicine for 3 weeks. They found that for patients in the colchicine group, the time to clinical deterioration improved, although there were no significant differences between the groups in cardiac and inflammatory biomarkers.

Segment Analysis

The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to hold the largest market share in global gout therapeutics market

The non-steroidal anti-inflammatory drugs (NSAIDs) are estimated to dominate the market, owing to the availability of these drugs at a lower cost compared to other drugs, high level of penetration of drugs, and the ability to relieve pain in case of an acute gout attack.

NSAIDs are the first-line drugs used to decrease the inflammation and the associated pain of rheumatic and non-rheumatic diseases. The rising number of gout patients, low cost of drugs, and application in combination therapy is likely to drive the market Indomethacin and naproxen are the major choice for the acute attack of gout.

NSAIDs decrease pain and swelling. Some NSAIDs are available over-the-counter, like ibuprofen and naproxen sodium. Stronger NSAIDs like indomethacin and celecoxib are prescribed by the doctor. Although NSAID effects on pain tend to be patient-specific, naproxen and indomethacin are common choices. Use of concomitant gastric protection with misoprostol or consideration of a cyclooxygenase-2 (COX-2)-specific NSAID might be considered if the patient has gastrointestinal (GI) risk or is older than 51 years.

To control the attack as quickly and safely as possible (recalling that it takes 5 half-lives to reach a steady state), NSAIDs with a short half-life (eg, ketoprofen, ibuprofen, or diclofenac) are preferred.

Geographical Analysis

North America region holds the largest market share in the global gout therapeutics market

North America is dominating the global gout therapeutics market, accounting for the largest market share, owing to the large presence of major players, high demand for gout therapy, and high cost of branded pharmaceuticals U.S. Also, the research and development of new drugs for gout treatment is expected to show dominance over the forecast period. In June 2020, Pharma major Dr. Reddy's Laboratories launched the generic Colchicine caused to prevent and treat acute gout flares in the US market.

The Asia Pacific region is expected to grow at the fastest growth rate over the forecast period owing to the diversified patient pool, and growing investment by major players with local manufacturers, and hospital chains in growing countries such as India, China, South Korea, and other South Asian countries. According to the Australian Institute of Health and Welfare report 2022, in 2017-2018, gout cost the Australian health system an estimated USD 196.5 million, representing 1.4% of disease expenditure on musculoskeletal conditions and 0.2% of total disease expenditure. Besides, changing lifestyles with a rising prevalence of smoking & alcohol consumption is expected to boost gout incidence over the period.

In December 2022, Selecta Biosciences, Inc., a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, completed the patient enrollment in the six-month, head-to-head, Phase 2 COMPARE clinical trial. The trial evaluates the superiority of a once-monthly dose of Selecta's lead product candidate, SEL-212 (ImmTOR + pegadricase), versus a bi-weekly dose of pegloticase, the current FDA-approved uricase therapy for adult patients with chronic refractory gout.

Demand for effective therapeutics for gout treatment is increasing. Numerous pipeline products and recent approvals of drugs to treat gout arthritis are expected to drive the market in the region. According to estimates more than 2 million people in the U.S. take medication to decrease serum uric acid levels. However, factors such as increasing competition in the generic sector, patent expiry of blockbuster products, and the high cost of the newly launched drugs are likely to hinder the growth of the market in the United States.

The Public Health Agency of Canada (PHAC), in collaboration with all Canadian provinces and territories, conducts national surveillance of gout and supports public health action.

Competitive Landscape

The global market for gout therapeutics is fragmented and highly competitive and consists of several major players. Few major players dominate the market share, and few emerging companies are expected to enter the market over the forecast period. Some of the market's major players market is Horizon Therapeutics plc, Lannett Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Ltd, and Mylan. The key players are adopting various growth strategies such as product launches, acquisitions, and collaborations, contributing to the global market's growth globally. For instance, On March 2nd, 2020, Avion Pharmaceuticals launched Gloperba (colchicine) oral solution for prophylaxis of gout flares in adults.

Companies are entering into collaborations, acquisitions, mergers, approvals and licensing for increasing their market penetration. In January 2020, US-based Novadoz Pharmaceuticals received FDA approval for their generic version of Febuxostat 40mg and 80mg tablets. The approved product is AB-rated to the brand Uloric, marketed by Takeda Pharmaceuticals America, Inc.

Key Companies to Watch

Novartis AG:

Overview: Novartis AG develops, manufactures, and markets healthcare products. The company mainly operates through three business segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of the cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics.

Product Portfolio:

Canakinumab: Canakinumab is a fully human monoclonal antibody targeting IL 1b that has an expanding list of clinical indications. Novartis' canakinumab, an IL-1B inhibitor, has shown remarkable clinical success in treating gout.

Key Developments: In Jun 2022, Novartis announced the approval of Cosentyx by the European Commission (EC). It is used for treatment of juvenile idiopathic arthritis (JIA) a category of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) in patients ages 6 years or older.

The global gout therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. Growing adoption of biologics
    • 4.1.1.2. Increasing R&D on regenerative medicines
  • 4.1.2. Restraints:
    • 4.1.2.1. Side effects associated with gout therapeutics
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Regulatory Analysis
• 5.3. Supply Chain Analysis
• 5.4. Pricing Analysis
• 5.5. Pipeline Analysis
• 5.6. Unmet Needs
• 5.7. Epidemiology

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Drug Class

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
  • 7.1.2. Market Attractiveness Index, By Drug Class Segment
• 7.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.2.3. Ibuprofen
  • 7.2.4. Naproxen
  • 7.2.5. Indomethacin
  • 7.2.6. Celecoxib
  • 7.2.7. Others
• 7.3. Anti-hyperuricemic Agents (Urate-Lowering Drugs)
  • 7.3.1. Xanthine oxidase inhibitors
    • 7.3.1.1. Allopurinol (Lopurin, Zyloprim)
    • 7.3.1.2. Febuxostat (Uloric)
  • 7.3.2. Uricosuric Medications
    • 7.3.2.1. Benzbromarone
    • 7.3.2.2. Probenecid
    • 7.3.2.3. Sulfinpyrazone
  • 7.3.3. Uricases
    • 7.3.3.1. Pegloticase
    • 7.3.3.2. Rasburicase
• 7.4. Corticosteroids
  • 7.4.1. Dexamethasone (DexPak)
  • 7.4.2. Methylprednisolone (Medrol)
  • 7.4.3. Prednisolone (Omnipred)
  • 7.4.4. Prednisone (Rayos)
  • 7.4.5. Triamcinolone (Aristospan)
• 7.5. Colchicine
  • 7.5.1. Colcrys
  • 7.5.2. Mitigare
• 7.6. Others

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 8.1.2. Market Attractiveness Index, By Application Segment
• 8.2. Acute Gout
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Chronic Gout

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
  • 9.1.2. Market Attractiveness Index, By End User Segment
• 9.2. Hospital Pharmacies
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Drug Stores
• 9.4. Online Channels
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Drug Class Benchmarking
• 11.4. List of Key Companies to Watch

12. Company Profiles

• 12.1. Novartis International AG
  • 12.1.1. Company Overview
  • 12.1.2. Drug Class Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. GlaxoSmithKline PLC
• 12.3. Lannett Company, Inc
• 12.4. Mylan NV
• 12.5. Boehringer Ingelheim
• 12.6. Horizon Therapeutics plc
• 12.7. Regeneron Pharmaceuticals
• 12.8. Takeda Pharmaceutical Company Ltd
• 12.9. Teijin Pharma Ltd
• 12.10. Romeg Therapeutics, LLC

LIST NOT EXHAUSTIVE

13. Global Gout Therapeutics Market - DataM

• 13.1. Appendix
• 13.2. About Us and Application
• 13.3. Contact Us